Table 3.
Event-free Survival | Overall Survival | |||||||
---|---|---|---|---|---|---|---|---|
Univariate | Multivariable | Univariate | Multivariable | |||||
HR (95CI) | P value | HR (95CI) | P value | HR (95CI) | P value | HR (95CI) | P value | |
Age at diagnosis (years) | ||||||||
<10 | Ref | Ref | Ref | Ref | Ref | Ref | Ref | Ref |
≥10 | 2.7 (2.4–2.9) | <0.0001 | 1.7 (1.5–1.9) | <0.0001 | 4.1 (3.6–4.8) | <0.0001 | 2.5 (2.2–3.0) | <0.0001 |
Sex | ||||||||
Female | Ref | Ref | Ref | Ref | Ref | Ref | Ref | Ref |
Male | 1.2 (1.1–1.3) | 0.003 | 1.2 (1.1–1.3) | 0.004 | 1.2 (1.0–1.3) | 0.047 | 1.2 (1.0–1.4) | 0.046 |
WBC at presentation (×109/L) | ||||||||
<50 | Ref | Ref | Ref | Ref | Ref | Ref | Ref | Ref |
≥50 | 2.1 (1.9–2.4) | <0.0001 | 1.6 (1.4–1.8) | <0.0001 | 2.3 (2.0–2.7) | <0.0001 | 1.5 (1.3–1.8) | <0.0001 |
CNS status | ||||||||
CNS1 | Ref | Ref | Ref | Ref | Ref | Ref | Ref | Ref |
CNS2 | 1.8 (1.5–2.0) | <0.001 | 1.4 (1.2–1.6) | <0.0001 | 1.9 (1.6–2.3) | <0.0001 | 1.4 (1.1–1.7) | 0.002 |
CNS3 | 1.7 (1.1–2.5) | 0.008 | 0.9 (0.6–1.5) | 0.82 | 2.2 (1.4–3.4) | 0.0006 | 1.0 (0.6–1.8) | 0.91 |
Cytogenetics | ||||||||
Favorable | Ref | Ref | Ref | Ref | Ref | Ref | Ref | Ref |
Neutral | 2.8 (2.5–3.3) | <0.0001 | 2.1 (1.8–2.5) | <0.0001 | 4.1 (3.3–5.1) | <0.0001 | 2.9 (2.3–3.8) | <0.0001 |
Unfavorable | 6.9 (5.7–8.2) | <0.0001 | 3.6 (2.9–4.5) | <0.0001 | 11.8 (9.3–15.2) | <0.0001 | 5.8 (4.3–7.9) | <0.0001 |
End of induction BM MRD | ||||||||
<0.01% | Ref | Ref | Ref | Ref | Ref | Ref | Ref | Ref |
≥0.01% | 3.7 (3.3–4.1) | <0.0001 | 2.9 (2.5–3.2) | <0.0001 | 4.3 (3.7–5.0) | <0.0001 | 2.9 (2.5–3.4) | <0.0001 |
95CI – 95% confidence interval; BM – bone marrow; CNS – central nervous system; HR – hazard ratio; MRD – minimal residual disease; WBC – white blood cells